HIV | ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study

HIV research study

What is the primary objective of this study?

The investigators propose a proof-of-concept, pathogenesis-oriented, randomized, placebo-controlled pilot study to assess whether the addition of an angiotensin converting enzyme (ACE) inhibitor to standard Highly Active Antiretroviral Therapy (HAART) reverses lymphoid fibrosis, and whether this leads to more effective HIV-specific host immune responses and an accelerated clearance of the latent reservoir.

Who is eligible to participate?

Inclusion Criteria include: - Stable HAART with maintenance of plasma HIV RNA levels below level of detection (< 40-75 copies/mL) for ≥ 12 months - > 90% adherence to HAART within preceding 30 days Exclusion Criteria include: - Screening systolic blood pressure < 110mm Hg or diastolic blood pressure < 60mm Hg - Current use of any ACE inhibitor, angiotensin receptor blocker, or aldosterone antagonist - Known diabetes mellitus or cardiovascular/kidney/collagen vascular disease - Pregnant/breastfeeding women.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:LisinoprilLisinopril 20mg QD x 24 weeks

Drug:PlaceboPlacebo QD x24wks

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

ACE InhibitorActive group

PlaceboPlacebo group

Study Status


Start Date: February 2012

Completed Date: December 2014

Phase: Phase 4

Type: Interventional


Primary Outcome: Change in HIV RNA (Copies/Million Rectal Cells)

Secondary Outcome: Change in HIV DNA (Copies/Million Rectal Cells)

Study sponsors, principal investigator, and references

Principal Investigator: Hiroyu Hatano, MD

Lead Sponsor: University of California, San Francisco

Collaborator: amfAR, The Foundation for AIDS Research

More information:

Discuss Lisinopril